146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trialElizabeth Fitzpatrick, P. McNally, B. Linnane et al.|Journal of Cystic Fibrosis|2024Cited by 0
WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoringP. McNally, H. Tiddens, K. Lester et al.|Journal of Cystic Fibrosis|2025Cited by 0